bcg (tokyo 172) vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT04453293)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04453293 | Phase 3 | Dec 1, 2021 | Department of Defense, Henry M. Jackson Foundation for the Advancement of Military Medicine, Uniformed Services University of the Health Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2021 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Uniformed Services University of the Health Sciences | Government | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1